Ipilimumab was approved as an anti-CTLA-4 monoclonal antibody (2011) for interrupting B27/CTLA-4 binding andrestoring T lymphocytes cytotoxicity.106 In a HIMALAYA clinical trial, tremelimumab (Imjudo), a CTLA4-targeting monoclonal antibody, coupled with durvalumab led to a longer OS (16.43 months) for liver cancer patients compared to 13.8 months for the sorafenib-treated group.107. This evidence concerns the gene CTLA4 and liver cancer.